EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod\u00a0\u00a0","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Famar","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of Laquinimod","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"GREECE","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Laquinimod

    Menu

    Laquinimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Famar

              Contact Supplier
              • Deals
              Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.
              Contact Supplier Contact Supplier
              Flag Greece
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of Laquinimod

              Details:

              Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.

              Lead Product(s): Laquinimod

              Therapeutic Area: Ophthalmology Product Name: ABR-215062

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Active Biotech

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 04, 2021

              Famar

              CPhI Worldwide, Milan

              Booth #5C27

              envelop Contact Supplier

              Active Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders

              Details:

              Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.

              Lead Product(s): Laquinimod

              Therapeutic Area: Ophthalmology Product Name: TV-5600

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Active Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod  

              Details:

              A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.

              Lead Product(s): Laquinimod

              Therapeutic Area: Ophthalmology Product Name: ABR-215062

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY